🔗 Share this article

As the US proceeds with sweeping changes to its vaccination guidelines, a particular individual has emerged in a surprising turn: Høeg, a US-based physician and public health researcher who initially gained attention by questioning Covid vaccines in the pandemic and has concentrated on potential deaths after COVID-19 vaccination in her brief tenure at the Food and Drug Administration.

Scheduled Shifts to Pediatric Immunization Schedule

Agency leaders were set to reveal radical changes to the pediatric vaccination calendar recently, bringing the US with the Danish vaccine program, sources say – a significant shift that would put the US out of alignment with a large portion of the world with insufficient data for improved outcomes. The planned update has been pushed back until the coming year.

Instead of the director of the vaccine center, Høeg is scheduled to address the audience at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to head the office this calendar year.

A Shift at the FDA

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a greater focus upon reevaluating previously authorized immunizations at the FDA.

The new acting director has often pushed for halting specific childhood vaccine recommendations in the US to become more like the Danish model, a country with comprehensive healthcare and a number of inhabitants roughly the size of the state of Wisconsin.

So far comments, she has kept her attention on vaccines – traditionally the responsibility of Dr. Prasad, head of the FDA’s vaccine center – rather than medication approval.

Doubts Over Expertise

The appointee has little discernible background in medication creation, oversight or administrative roles, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and CBER since March.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She’s never run a scientific study. She lacks experience in running a sizeable institution. She is not an expert in pharmaceutical oversight.”

Past directors of the center would “be deeply familiar with regulatory frameworks and the science of medication creation”, commented a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that prior appointees who ran CBER have had.”

This division has an immense range of responsibilities at the agency, she emphasized.

“Everybody just pays attention on the novel medication approvals, but the generic program clears numerous off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and other areas, and every single one must be managed,” Woodcock noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a substantial leadership element to the job, which manages over 5,000 personnel. “It’s a huge leadership role, if you perform it correctly,” the former official said.

Response and Contentious Policies

When asked about concerns about Dr. Høeg's fitness for the role and whether this appointment signifies increased cooperation among regulatory chiefs on immunizations, a spokesperson stated that the “questions rely on inaccurate premises”.

“This background is consistent with the duties of her job,” the official stated, pointing to the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg takes over the commissioner’s controversial priority voucher program, a disputed rapid drug-approval program that apparently concerned her former heads. “How are these drugs being picked for this expedited pathway? Who makes the decisions?” Howard asked. “There’s a lot of lack of transparency occurring at the FDA right now.”

Overall, he remarked, “the agency seems to be moving towards laxer regulations of most medications, except for immunizations.”

Public Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if troubling, history, some experts said. She released a analysis using unconfirmed volunteer-provided data to determine the incidence of heart inflammation after Covid vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are more dangerous than they are.

Part of her “policy goals” for the new federal leadership encompassed revising rules for recently developed shots and ending “non-essential” vaccines, she remarked post-election on a online show. At the agency, Høeg has allegedly proposed barring adolescent males from receiving COVID-19 vaccinations.

“She’s an all-around dogmatist who begins with her beliefs and works backwards to retrofit the science in a highly deceptive, untruthful way,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg aligned with fellow dissenters, {like|